Cargando…
The Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies
Immunotherapy of cancer had its early beginnings in the times when the elements of the immune system were still poorly characterized. However, with the progress in molecular biology, it has become feasible to re-engineer T cells in order to eradicate tumour cells. The use of synthetic chimeric antig...
Autores principales: | Zhylko, Andriy, Winiarska, Magdalena, Graczyk-Jarzynka, Agnieszka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466082/ https://www.ncbi.nlm.nih.gov/pubmed/32722109 http://dx.doi.org/10.3390/cancers12082030 |
Ejemplares similares
-
The Tumor Microenvironment—A Metabolic Obstacle to NK Cells’ Activity
por: Domagala, Joanna, et al.
Publicado: (2020) -
PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells
por: Bajor, Malgorzata, et al.
Publicado: (2022) -
P1376: IDENTIFICATION OF SURFACEOME CHANGES IN CD19 CAR-T THERAPY-RESISTANT LYMPHOMA CELLS
por: Krawczyk, Marta, et al.
Publicado: (2023) -
PRDX-1 Supports the Survival and Antitumor Activity of Primary and CAR-Modified NK Cells under Oxidative Stress
por: Klopotowska, Marta, et al.
Publicado: (2022) -
New insights into redox homeostasis as a therapeutic target in B-cell malignancies
por: Graczyk-Jarzynka, Agnieszka, et al.
Publicado: (2017)